An agreed PIP is the regulatory pathway to market authorization for leniolisib as a treatment of activated phosphoinositide 3-kinase delta syndrome in children. Pharming announces that a positive decision has been made by the European Medicines Agency (EMA) on the Paediatric Investigation Plan